

PATENT
603-1-009IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): HENRY W. FOUNDS et al.

SERIAL NO.: 08/367,507 EXAMINER: Adams, D.

FILED: December 30, 1994 ART UNIT: 1816

FOR: MONOCLONAL ANTIBODY SPECIFIC FOR ADVANCED
GLYCOSYLATION ENDPRODUCTS IN BIOLOGICAL SAMPLES

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on February 3, 1997

Paul E. Fehlner Reg. No. 35,135
(Name of Registered Representative)

Paul E. Fehlner 2/3/97
(Signature and Date)

DECLARATION CONCERNING DEPOSIT OF
HYBRIDOMA FOR PATENT PURPOSES

Veronica Mallon, Ph.D., Vice President, Scientific Communications and Intellectual

Property, hereby states that:

1. Alteon Inc., a corporation of the State of Delaware, having offices at 170 Williams Drive, Ramsey, New Jersey, is assignee of the entire right, title, and interest in, to, and under the above-identified application by virtue of an assignment by the inventors recorded on Reel 7594, frame 0681.

2. Hybridoma 5D2-4D6-4G9 was deposited by Henry W. Founds on behalf of Alteon Inc., with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852, under the provisions of the Budapest Treaty of the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure on April 27, 1994, and was

FEB 03 '97 03:47PM ALTEON INC
FEB-03-97 JUN 14:40


P.3/3/03

assigned accession number CRL 11626.

3. In accordance with the Budapest Treaty and the Patent Laws and Rules,
 - (a) during the pendency of this application, access to the deposit will be afforded to the Commissioner upon request;
 - (b) all restrictions upon the availability to the public of the deposited biological material will be irrevocably removed upon the granting of a patent on this application;
 - (c) the deposit will be maintained in a public depository for a period of at least thirty years from the date of deposit or for the enforceable life of the patent or for a period of five years after the date of the most recent request for the furnishing of a sample of the deposited biological material, whichever is longest; and,
 - (d) the deposit will be replaced if it should become nonviable or non-replicable.

4. It is declared by the undersigned that all statements made herein of the undersigned's own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Title 18 of the U.S. Code, Section 1001 and that such willful false statements may jeopardize the validity of this Application or any patent issuing thereon.

DATED: 2/3/97


Veronica Mallon, Ph.D.
Vice President, Scientific Communications and
Intellectual Property
Alteon Inc.
Ramsey, New Jersey 07446